Purchase this article with an account.
Paolo Lanzetta, Valentina Sarao, Daniele Veritti; Ranibizumab in neovascular age-related macular degeneration: an as-needed treatment regimen with bimonthly evaluation. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5377.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Intravitreal therapies directed against vascular endothelial growth factor (VEGF) have dramatically improved the visual prognosis of choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). Debate exists regarding the best treatment and monitoring regimen for patients treated with intravitreal ranibizumab. <br /> A clinical study was conducted to evaluate the efficacy and safety of bimonthly pro-re-nata (PRN) intravitreal ranibizumab for the treatment of CNV secondary to AMD.
Thirty patients affected by CNV due to AMD received an intravitreal ranibizumab injection at baseline then PRN. Patients were scheduled for bimonthly follow-up visit examinations. Unscheduled visits and rescue injections were allowed at investigator’s discretion or based on patient-reported outcomes. As-needed and rescue treatments were performed over a 12-month follow-up period on the basis of functional or morphological criteria. The primary outcome was the average best-corrected visual acuity change at one year. Secondary outcomes were central retinal thickness changes, number of injections, number of rescue visits and treatments. Safety data were recorded.
The study included 30 eyes with CNV secondary to AMD. At 12 months mean (±SD) visual acuity improvement was -0.13 (±0.23) logMAR (p<0.001) and macular thickness decreased on average by -102 (±151) µm (p<0.0001). Twenty-three percent of patients underwent a rescue visit and 13% of eyes required rescue treatment. The majority of rescue evaluations were performed at physician’s discretion. Patients received a mean of 4 injections. No significant adverse event was observed during the follow-up.
Pro-re-nata ranibizumab administration with bimonthly evaluations produced significant functional and morphological improvements and may be a valide choice to reduce the burden of monitoring visits and injections.
This PDF is available to Subscribers Only